We have significant experience treating not only straightforward abdominal aortic aneurysms (AAA), but those that require complex or hybrid techniques.
Medical Services related to David M. Williams MD
At the University of Michigan, our Advanced Interventional Cardiology Program offers comprehensive and individualized care, utilizing the latest technologies currently available for angioplasty and stenting, performed by our skilled team of interventional cardiologists.
University of Michigan Frankel Cardiovascular Center Aortic Disease program began in 1995 and has a long history of treating all types of aortic disease.
Our mortality rate for open acute aortic dissection repairs is 5.4 percent over the past 5 years, much less than the national average of 25 percent.
We offer multiple treatments for aortic valve disease, including both open-heart surgery and TAVR for those who are at risk for open surgery.
We treat connective tissue disorders including Marfan's syndrome, Ehlers-Danlos syndrome and Loeys-Dietz syndrome, which can affect the aorta.
University of Michigan Aortic Disease Program treats all kinds of arterial disease, including arteriosclerotic aortic disease (hardening of the arteries).
The Fenestrated Endograft (FEVAR) is a relatively new minimally-invasive option for people with abdominal aortic aneurysms who don’t qualify for traditional endovascular aneurysm repair (EVAR). The unique feature of fenestrated endografts is that they can cover branch arteries of the aorta (such as the renal arteries) because the graft has fenestrations, or holes, that correspond to the position of the branching arteries within the aorta to allow for blood to flow through the graft into the branch vessel.
Common questions and answers about aortic disease, including aortic valve disease, aortic aneurysms, enlarged aorta, and aortic valve disease. Includes appointment and insurance information.
Hereditary Hemorrhagic Telangiectasia (HHT) is a genetic disorder that affects about one in 5000 people and commonly causes nosebleeds, with more frequent nosebleeds typically starting after about age 12. Patients with HHT have a tendency to form blood vessels that are abnormal, fragile, and bleed more easily.
Pulmonary emboli can present as acute PE or chronic PE. Acute PE is a new obstruction causing acute onset heart strain and often needs immediate treatment with clot busters and blood thinning medications. Chronic PE is a more insidious presentation that includes heart failure with gradual progressive symptoms and is caused by an older residual obstruction resulting from an undissolved clot in the pulmonary circulation left over from previous acute pulmonary emboli. In addition, in a small percentage of patients, chronic PE can lead to elevated blood pressure in the pulmonary arteries over time, developing into a rare type of pulmonary hypertension called chronic thromboembolic pulmonary hypertension (CTEPH).
A thoracic aortic aneurysm is an enlargement in the upper part of the aorta, the major blood vessel that routes blood to the body. Thoracic aortic aneurysms can cause aortic dissection (splitting of the aortic wall) and aortic rupture, leading to life-threatening internal bleeding. Thoracic aortic aneurysms, even those that are large, frequently do not cause symptoms. Some individuals, however, may experience symptoms such as: pain in the chest area; back pain; coughing or hoarseness; and difficulty breathing.
Thoracic endovascular aortic repair (TEVAR) is a minimally invasive option to conventional open surgery for patients suffering from thoracic aortic aneurysms (TAAs) who are not optimal candidates for traditional open repair. TEVAR can shorten hospital stays and reduce recovery periods. The University of Michigan Frankel Cardiovascular Center’s surgical team has more than two decades of experience performing TEVAR procedures and provides comprehensive care to patients with thoracic aortic aneurysms as well as to all aortic patients, including those who are high-risk.